|Videos|May 27, 2016
An Increased Emphasis on Individual Risk Factors and Goals
Advertisement
Episodes in this series
Zachary T. Bloomgarden, MD, MACE: We talked about lipid-lowering treatment and the notion that the idea of goals has recently been questioned. So, I certainly think that goals are a good way of treating cholesterol, but there are some controversies about that.
We use goals in treating all medical conditions. We use goals in treating blood pressure—we have to decide what the right blood pressure goal is for a given individual and then aim for that. We use goals in treating diabetes—we have to decide what the right A1C goal or fasting plasma glucose goal is for a given individual, and then stay with that. I’m completely in favor of the use of goals, as long as we do it in a rational fashion and apply it correctly.
Advertisement
Related to this article
Low awareness that fatty liver can silently progress and that MASH fibrosis is treatable drives missed follow-up testing, says Rohit Loomba, MD.
The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.
In this Q&A, Christie Ballantyne, MD, explains why consistent LDL-C lowering with oral enlicitide could expand PCSK9 use in primary prevention.
Independent VESALIUS-CV analysis finds evolocumab cost-effective at about 36% below the ACC/AHA benchmark for patients without prior MI or stroke.
Experts at GOLD 2026 say targeted case finding, AI, and guideline-based treatment can close COPD’s diagnostic gap and improve patient outcomes.
Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.
Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.
Advertisement
Advertisement
Trending on AJMC
1
Real-World Cohort Ties JAK Inhibitors in Alopecia Areata to Menstrual Side Effects
2
Phase 3 Trial Tests Ensifentrine for COPD Exacerbation Prevention
3
Trends in Pharmacy Benefit Manager Market Dynamics, 2016-2025
4
Tarlatamab Plus Durvalumab Cuts Risk of Death by 58% as First-Line Maintenance in ES-SCLC
5